Retrophin Inc. (RTRX) Sees Unusually-High Trading Volume
Retrophin Inc. (NASDAQ:RTRX) shares saw unusually-high trading volume on Monday . Approximately 527,147 shares changed hands during trading, an increase of 16% from the previous session’s volume of 456,285 shares.The stock last traded at $18.27 and had previously closed at $17.93.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 6th. Leerink Swann restated a “buy” rating on shares of Retrophin in a report on Wednesday, May 11th. BMO Capital Markets restated a “buy” rating on shares of Retrophin in a report on Wednesday, May 4th. Finally, JMP Securities restated a “buy” rating on shares of Retrophin in a report on Saturday, July 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $23.60.
The company has a market cap of $666.40 million and a PE ratio of 9.46. The firm’s 50-day moving average is $17.92 and its 200-day moving average is $15.92.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.36. During the same quarter in the previous year, the business posted ($0.18) EPS. The company earned $29 million during the quarter, compared to analyst estimates of $31 million. The company’s revenue was up 66.7% compared to the same quarter last year. Equities research analysts expect that Retrophin Inc. will post $0.08 earnings per share for the current year.
In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the firm’s stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $17.75, for a total value of $155,312.50. Following the completion of the sale, the executive vice president now owns 167,084 shares in the company, valued at approximately $2,965,741. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
An institutional investor recently raised its position in Retrophin stock. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Retrophin Inc. (NASDAQ:RTRX) by 1,449.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 91,421 shares of the biopharmaceutical company’s stock after buying an additional 85,521 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.25% of Retrophin worth $1,763,000 as of its most recent filing with the SEC.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.